



(51) International Patent Classification:

A61K 47/68 (2017.01) C07D 205/04 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2024/072929

(22) International Filing Date:

14 August 2024 (14.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/519,567 15 August 2023 (15.08.2023) US
63/673,817 22 July 2024 (22.07.2024) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85
Södertälje (SE).(72) Inventors: **BEADLE, Jonathan David**; c/o AstraZeneca
UK Limited, 1 Francis Crick Ave., Cambridge Biomed-
ical Campus, Cambridge CB2 0AA (GB). **GALAN CO-
CA, Albano**; c/o AstraZeneca UK Limited, 1 Francis Crick
Ave., Cambridge Biomedical Campus, Cambridge CB2
0AA (GB). **COCCO, Mattia**; c/o AstraZeneca UK Lim-
ited, 1 Francis Crick Ave., Cambridge Biomedical Cam-
pus, Cambridge CB2 0AA (GB). **GOUNDRY, William**


Robert Fraser; c/o AstraZeneca UK Limited, 1 Francis
Crick Ave., Cambridge Biomedical Campus, Cambridge
CB2 0AA (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-
TY**; Eastbrook House Shaftesbury Road, Cambridge, Cam-
bridgeshire CB2 8BF (GB).

(81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: CONJUGATES COMPRISING CLEAVABLE LINKERS



(57) **Abstract:** The specification relates to conjugates comprising a
linker of Formula (IMA); and pharmaceutically acceptable salts thereof.
The specification also relates the use of the conjugates for the treatment
of diseases such as cancer, and intermediates useful for the synthesis of
the conjugates.




Figure 2B

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*